PRODUCT

Tesamorelin (5 mg Vial)

No short description available.

Quickstart Highlights

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research[3][4].

Reconstitute: Add 2.5 mL bacteriostatic water per 5 mg vial → 2.0 mg/mL concentration.
Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
Easy measuring: At 2.0 mg/mL, 1 unit = 0.01 mL = 20 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); reconstituted: refrigerate and use within 7 days with bacteriostatic water.

Molecular Info

Chain Length:44 amino acids
Sequence Type:GHRH analog
Molecular Weight:5,135.9 Da
Amino Acid Sequence:His-Ala-Asp-Gly-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Modification:Modified with trans-3-hexenoic acid at N-terminus for enhanced stability

Research Indications

Weight Loss

moderate

HIV-Associated Lipodystrophy
FDA-approved indication showing 15-20% visceral fat reduction in clinical trials
Selective Visceral Fat Targeting
Unique mechanism spares subcutaneous fat while reducing harmful visceral adiposity
Sustained Fat Loss
Maintained weight loss with continuous treatment over 52+ weeks in clinical studies

Metabolic

effective

Triglyceride Reduction
12.3% triglyceride reduction demonstrated in pooled analysis of clinical trials
Cholesterol Profile Improvement
7.2% improvement in cholesterol/HDL ratio with daily 2mg dosing
NAFLD Treatment
37% liver fat reduction over 12 months in HIV patients with fatty liver disease

Musclegrowth

effective

Lean Muscle Mass Preservation
Maintains muscle mass during fat loss, unlike conventional weight loss methods
Muscle Density Enhancement
Improved muscle composition and density through IGF-1 mediated mechanisms
IGF-1 Elevation
26% increase in IGF-1 levels supporting muscle growth and recovery processes

Reconstitution

Draw 2.5 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Interactions

Ipamorelin

Monitor Combination

Synergistic GH stimulation possible. Monitor IGF-1 levels closely and consider dose adjustments to prevent excessive growth hormone elevation.

CJC-1295

Use Caution

Both bind to pituitary GHRH receptors. Combining saturates receptors without amplifying GH release, risking receptor desensitization and blunted pulsatility. Choose one based on your protocol goals.

CJC-1295 with DAC

Avoid Combination

Both target GHRH receptors but with conflicting release patterns. Tesamorelin promotes pulsatile GH release while DAC provides continuous stimulation, disrupting natural GH rhythms and accelerating receptor downregulation.

Sermorelin

Dose Dependent

Similar GHRH mechanism but Tesamorelin has longer half-life. Low doses may be complementary, but higher doses risk excessive GH stimulation.

Insulin

Monitor Combination

Tesamorelin increases diabetes risk (3.3-fold). Monitor blood glucose closely and adjust insulin doses as needed during treatment.

Metformin

Compatible

No direct interactions reported. May help mitigate glucose intolerance risk associated with Tesamorelin therapy.

Prednisone

Use Caution

Decreases corticosteroid effectiveness. Consider increasing steroid doses or using alternative anti-inflammatory therapy.

Octreotide

Avoid Combination

Somatostatin analog directly blocks GH release, completely negating Tesamorelin's therapeutic effects.

Growth Hormone

Avoid Combination

Redundant and potentially dangerous combination. Risk of acromegaly and metabolic complications from excessive GH exposure.

Protocol Overview

Goal:Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation[3][4].
Schedule:Daily subcutaneous injections for 12–26 weeks (extendable to 52 weeks with medical supervision)[3].
Dose:2 mg (2000 mcg) daily after Week 1 titration.
Reconstitution:2.5 mL per 5 mg vial (2.0 mg/mL) for accurate measurement.
Storage:Lyophilized refrigerated; reconstituted refrigerated up to 7 days; avoid freeze-thaw.

Dosage Protocols

Week 1:1 mg (1000 mcg) once daily to assess tolerability.
Weeks 2+:2 mg (2000 mcg) once daily (standard FDA-approved dose)[7][8].
Frequency:Once per day (subcutaneous), preferably in the evening.
Cycle Length:12–26 weeks; clinical trials support up to 52 weeks with monitoring[3].
Timing:Evening administration recommended; rotate injection sites.

Dosage Protocols

HIV Lipodystrophy (FDA Approved):1.4 mg dailyOnce daily
Visceral Fat Reduction:2 mg dailyOnce daily
Anti-aging/Body Composition:1-2 mg daily5-7 days/week
NAFLD Treatment:2 mg dailyOnce daily
Cognitive Enhancement (Research):1 mg dailyOnce daily
Research Protocol:1-2 mg dailyDaily

Route:injectable

Storage Instructions

Lyophilized:Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution[1].
Reconstituted:Proper storage preserves peptide quality and efficacy. Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution[1]. Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days[1]. Reconstituted (with sterile water): Use immediately; discard any unused portion[1]. Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container[10].
Rotate injection sites (abdomen at least 2 inches from navel, thighs, upper arms) to reduce local irritation[6][10].
Inject slowly; wait a few seconds before withdrawing the needle.
Monitor IGF-1 levels periodically due to potent GH stimulation; observe blood glucose in diabetic patients[9].
Document daily dose and site rotation to maintain consistency.

Reconstitution

Remove vial from refrigerator (powder should be stored at 2-8°C) and allow to reach room temperature
Egrifta SV: Add 0.5 mL sterile water to 2 mg vial
Egrifta WR: Add 1.3 mL bacteriostatic water to 11.6 mg vial
Gently swirl to dissolve - do not shake vigorously to prevent protein denaturation
Solution should be clear and colorless - do not use if cloudy or contains particles
Withdraw appropriate dose (typically 0.35 mL for 1.4 mg from SV preparation)
Inject subcutaneously in abdomen, rotating sites to prevent lipodystrophy
SV: Use immediately after mixing, discard any remaining solution. WR: Store at room temperature (20-25°C) for up to 7 days — do NOT refrigerate as it may cause precipitation

Route:injectable

How It Works

Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation[2]. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months[3][4]. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines[4].

Lifestyle Factors

Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects.
Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits.
Prioritize 7–9 hours of quality sleep to optimize natural GH pulsatility.
Manage stress through mindfulness or relaxation techniques to support adherence and recovery.

Injection Technique

Clean the vial stopper and skin with alcohol swabs; allow to air-dry completely.
Pinch a skinfold at the injection site (abdomen preferred, at least 2 inches from navel)[6].
Insert the needle at 90° (if adequate subcutaneous fat) or 45° (if lean)[10].
Release the pinch, then inject slowly; wait 2–3 seconds before withdrawing.
Rotate injection sites systematically (left/right abdomen, thighs, upper arms) to prevent lipohypertrophy[6].
Dispose of used syringes immediately in a puncture-proof sharps container[10].

Benefits and Side Effects

Benefits

Observations from clinical trials and FDA-approved use.

Tesamorelin (5 mg Vial)

Resources

Categories

Company